Stakeholder Perspective

As drug pricing for Medicare continues to be debated in Congress, drug manufacturers remain under scrutiny; however, several drug manufacturers (ie, AbbVie, Allergan, Johnson & Johnson, Merck, NovoNordisk) have pledged to contain drug price increases to under 10%.

Healthcare in the United States has experienced a tremendous amount of reform and innovation, especially in the past 10 years, with an emphasis on improving value. Value in healthcare is driven by increasing quality of care while reducing cost. The evolution of quality measurement has been proactive and voluntary within national organizations, such as the National Quality Forum.1 Reform has been less voluntary through government mandates, such as the Affordable Care Act (ACA).

Results 1 - 2 of 2
  • American Health & Drug Benefits
  • Lynx CME
  • Value-Based Care in Myeloma
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology